MiMedx Group, Inc. Aktie News

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

MARIETTA, Ga., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 16 th Annual Alpha Select Conference | New York, NY Tuesday, November 18, 20251:1 sessions Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New...

MiMedx Group is positioned for growth, with strong earnings, record Q3 revenue, and a rising contribution from its Surgical business. MDXG is proactively managing 2026 reimbursement policy risks by shifting product mix, accepting near-term price pressure, and leveraging its MiMedx Connect platform. Valuation analysis suggests MDXG is undervalued by ~20%, with feasible revenue growth and FCF mar...

MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday.

MiMedx Group, Inc. ( MDXG ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Matthew Notarianni - Head of Investor Relations Joseph Capper - CEO & Director Douglas Rice - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Carl Byrn...

Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Confer...

MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:3...

Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products